Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

1. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment 30420184 2018 11 13 1879-1913 2018 Oct 19 The American journal of cardiology Am. J. Cardiol. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. S0002-9149(18)31970-2 10.1016/j.amjcard.2018.09.041 High-dose statin (HDS) therapy is recommended to reduce (...) low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine) can lead to a higher proportion of high-risk patients achieving target LDL-C. A secondary objective was to assess the efficacy of triple

2018 EvidenceUpdates

2. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. (PubMed)

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. BACKGROUND: Cardiovascular disease (CVD) remains an important cause of mortality and morbidity, and high levels of blood cholesterol are thought to be the major modifiable risk factors for CVD. The use of statins is the preferred treatment strategy for the prevention of CVD, but some people at high-risk for CVD are intolerant to statin therapy or unable to achieve their treatment goals with the maximal (...) recommended doses of statin. Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events remains uncertain. Results from clinical studies are inconsistent and a thorough evaluation of its efficacy and safety for the prevention of CVD and mortality is necessary. OBJECTIVES: To assess the efficacy and safety of ezetimibe for the prevention of CVD and all-cause mortality. SEARCH METHODS: We searched the CENTRAL, MEDLINE, Embase and Web of Science on 27 June 2018

2018 Cochrane

3. Ezetimibe

Ezetimibe Top results for ezetimibe - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ezetimibe The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

4. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) 28972004 2017 12 26 2017 12 26 1524-4539 136 25 2017 Dec 19 Circulation Circulation Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 2440-2450 10.1161 (...) /CIRCULATIONAHA.117.029095 Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial

Full Text available with Trip Pro

2018 EvidenceUpdates

5. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) 28750828 2017 07 28 2017 08 06 1879-1913 2017 Jun 28 The American journal of cardiology Am. J. Cardiol. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). S0002-9149(17)31031-7 10.1016/j.amjcard.2017.06.023 The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C (...) ). Demonstrating whether efficacy and safety are maintained over a long duration of exposure is vital for clinical decision-making. The COMBO II trial compared the efficacy and safety of alirocumab versus ezetimibe over 2 years. A prespecified first analysis was reported at 52 weeks. Here we report the final end-of-study data (on-treatment) and evaluate post hoc the safety profile with longer versus shorter duration of alirocumab exposure. Patients (n = 720) on maximally tolerated statin dose were treated

Full Text available with Trip Pro

2017 EvidenceUpdates

6. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial 28430910 2017 04 21 2017 04 21 1522-9645 2017 Apr 18 European heart journal Eur. Heart J. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial (...) . 10.1093/eurheartj/ehx162 To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less than 100 mg/dL (2.6 mmol/L). The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe

Full Text available with Trip Pro

2017 EvidenceUpdates

7. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia 27756478 2016 10 19 2017 05 01 2017 05 01 1879-1913 118 12 2016 Dec 15 The American journal of cardiology Am. J. Cardiol. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. 1812-1820 S0002-9149(16)31478-3 10.1016/j.amjcard.2016.08.071 Statin therapy is associated with a slightly increased risk of developing (...) diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients

Full Text available with Trip Pro

2016 EvidenceUpdates

8. LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs

LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs LIPTRUZET SUMMARY CT14103

2016 Haute Autorite de sante

9. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. (PubMed)

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 27039291 2016 04 20 2016 05 01 2016 10 17 1538-3598 315 15 2016 Apr 19 JAMA JAMA Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 1580-90 10.1001/jama.2016.3608 Muscle-related statin intolerance is reported by 5% to 20% of patients. To identify patients (...) with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab. Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo

Full Text available with Trip Pro

2016 JAMA

10. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia Ezetimibe for treating primary Ezetimibe for treating primary heterozygous-familial and non-familial heterozygous-familial and non-familial h hypercholesterolaemia ypercholesterolaemia T echnology appraisal guidance Published: 24 February 2016 nice.org.uk/guidance/ta385 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (PubMed)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) 26597925 2016 03 25 2016 08 01 2017 03 24 1523-6838 67 4 2016 Apr American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). 576-84 10.1053/j.ajkd (...) .2015.09.020 S0272-6386(15)01251-2 Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled trial. 9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus placebo; participants in categories

Full Text available with Trip Pro

2016 EvidenceUpdates

12. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease (PubMed)

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease 26611120 2015 11 27 2016 03 15 2015 11 27 1879-1913 116 12 2015 Dec 15 The American journal of cardiology Am. J. Cardiol. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. 1798-801 10.1016/j.amjcard.2015.09.023 S0002-9149(15)02002-0 (...) Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective, and parallel group trial comparing a combination of nutraceuticals (red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin), called

2015 EvidenceUpdates

13. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT (PubMed)

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT 26330412 2015 09 29 2016 01 05 2016 07 28 1524-4539 132 13 2015 Sep 29 Circulation Circulation Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better (...) outcomes in IMPROVE-IT. 1224-33 10.1161/CIRCULATIONAHA.115.018381 Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). The IMPROVE-IT trial randomly

Full Text available with Trip Pro

2015 EvidenceUpdates

14. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444735 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1473. doi: 10.1056/NEJMc1509363#SA1. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444735 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

Full Text available with Trip Pro

2015 NEJM

15. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444734 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1476-7. doi: 10.1056/NEJMc1509363. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26444734 DOI: [Indexed

Full Text available with Trip Pro

2015 NEJM

16. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444737 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1474. doi: 10.1056/NEJMc1509363#SA3. Ezetimibe plus a Statin after Acute Coronary Syndromes. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444737 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How

Full Text available with Trip Pro

2015 NEJM

17. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444736 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1473-4. doi: 10.1056/NEJMc1509363#SA2. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444736 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

Full Text available with Trip Pro

2015 NEJM

18. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444738 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1474-5. doi: 10.1056/NEJMc1509363#SA4. Ezetimibe plus a Statin after Acute Coronary Syndromes. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444738 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

Full Text available with Trip Pro

2015 NEJM

19. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444739 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1475. doi: 10.1056/NEJMc1509363#SA5. Ezetimibe plus a Statin after Acute Coronary Syndromes. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444739 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How

Full Text available with Trip Pro

2015 NEJM

20. Ezetimibe plus a Statin after Acute Coronary Syndromes. (PubMed)

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444741 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1476. doi: 10.1056/NEJMc1509363#SA7. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444741 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

Full Text available with Trip Pro

2015 NEJM